Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 24 tags : Fda save search
FDA Grants Marketing Authorization to Siemens Healthineers ELF Test for NASH Prognostic Assessment
Published: 2021-08-24 (Crawled : 18:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.11%
H: 0.08%
C: -0.52%
fda test nash authorized granted grant
Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis
Published: 2021-08-24 (Crawled : 13:15) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 0.23%
H: 4.62%
C: 2.94%
treatment fda fda approval approval
PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: -22.37%
H: 18.5%
C: 17.25%
new drug fda drug skin application
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2021-08-24 (Crawled : 13:00) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseasePhase 3 Study Initiation Still Expected Fall 2021
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
Published: 2021-08-24 (Crawled : 12:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.35%
H: 0.12%
C: -0.9%
disease fda fda approval
Stealth BioTherapeutics Submits Elamipretide New Drug Application to FDA for Treatment of Barth Syndrome
Published: 2021-08-24 (Crawled : 12:00) - biospace.com/
MITO | $0.32 0.25%
|
Health Technology
|
| O: 3.42%
H: 0.0%
C: -1.65%
new drug treatment fda drug iot application syndros elamipretide
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)
Published: 2021-08-24 (Crawled : 12:00) - biospace.com/
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 11.21%
H: 1.41%
C: -8.06%
covid treatment fda potential results syndros
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Published: 2021-08-24 (Crawled : 07:00) - biospace.com/
CARA | $0.6816 -1.22% -1.23% 350K
|
Health Technology
|
| O: 21.08%
H: 5.55%
C: -13.94%
treatment fda hemodialysis fda approval injection approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.